Fig. 1: Overall data-driven high-throughput screening framework.

a Selection of patients from the INSIGHT and OneFlorida+ EHR warehouses, March 2020 to November 2021. b High-throughput construction of PASC-specific case and control groups that patients did not have target condition at baseline. c Study design. The PASC outcomes were ascertained from day 30 after the SARS-CoV-2 infection and the adjusted risk was computed 180 days after the SARS-CoV-2 infection. d Adjustment for baseline covariates by using stabilized inverse probability of treatment weighting (IPTW). e Likely PASC conditions were identified in the INSIGHT and OneFlorida+ cohorts respectively. Identified PASC were compared between the two cohorts. EHR electronic health records, PASC post-acute sequelae of SARS-CoV-2 infection.